Physician profile
Ramon Perea
NPI 1225178874
$68,225.54
in general payments reported to CMS, 2019-2025
14 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $4,780 · 2021: $4,686 · 2022: $7,618 · 2023: $14K · 2024: $8,874 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $1,637 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,018.40 |
| Food and Beverage | $1,636.71 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $50,413.64 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $16,368.26 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $329.21 | 2019-2025 | Lokelma, Farxiga |
| Abbott Laboratories | $206.49 | 2019-2025 | Amplatzer Amulet |
| Merck Sharp & Dohme LLC | $181.15 | 2019-2025 | Winrevair, Capvaxive |
| Pbg Puerto Rico LLC | $145.11 | 2020-2025 | |
| Boston Scientific Corporation | $141.57 | 2020-2025 | Watchman Access System, General - Therapies |
| Medtronic, INC. | $134.34 | 2023 | Corevalve Evolut R |
| Amgen INC. | $96.73 | 2020-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.70 | 2022-2025 | Jardiance |
| Bayer Puerto Rico INC. | $45.33 | 2025 | Kerendia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.91 | 2019-2020 | |
| Abbvie INC. | $25.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Perea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.